Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says

A recent study has discovered that the diabetes and weight-loss drug semaglutide, sold under the brand names Ozempic and Wegovy, may lower the risk of Alzheimer's disease. Researchers from Case Western Reserve School of Medicine analyzed electronic records of nearly one million Americans with type 2 diabetes and found that those using semaglutide were 40% to 70% less likely to receive an Alzheimer's diagnosis compared to those on other anti-diabetic drugs.

Professor Rong Xu, who led the study, believes the drug's anti-inflammatory, neuron-protecting, and weight-loss properties contribute to its potential to prevent or slow down Alzheimer's symptoms. However, the study does not definitively confirm semaglutide's impact on Alzheimer's risk outside of those with diabetes. Further research is needed, but Xu is hopeful about the findings' implications for Alzheimer's management.